Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + apatinib + nab-paclitaxel for recurrent extensive-stage small cell lung cancer
ChiCTR2300072520Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab, Rivoceranib and paclitaxel in small cell lung cancer (SCLC), sponsored by Henan Cancer Hospital. Primary endpoint: 1-year survival rate. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
adebrelimabRivoceranibpaclitaxel
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2300072520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072520.